Adaptimmune Therapeutics Plc Financials
Adaptimmune Therapeutics Plc (ADAPY) reported $178.0M in revenue for fiscal year 2024, up 195.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Adaptimmune’s high-margin revenue jump materially reduced operating losses, yet the business still depends on external capital to fund itself.
The operating loss narrowed from-$139.7M to-$68.8M , showing that FY2024’s revenue scale finally absorbed a meaningful share of the fixed cost base that had dominated prior years. Yet cash still declined even after a$78.7M financing inflow, so better reported performance has not crossed the line into self-funding operations.
FY2024’s gross margin was nearly
Short-term liquidity looks workable, with a current ratio of 2.9x and
Financial Health Signals
Adaptimmune Therapeutics Plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Adaptimmune Therapeutics Plc scores -5.80, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.0M) relative to total liabilities ($234.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Adaptimmune Therapeutics Plc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Adaptimmune Therapeutics Plc reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Adaptimmune Therapeutics Plc reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Adaptimmune Therapeutics Plc generated $178.0M in revenue in fiscal year 2024. This represents an increase of 195.3% from the prior year.
Adaptimmune Therapeutics Plc's EBITDA was -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.7% from the prior year.
Adaptimmune Therapeutics Plc reported -$70.8M in net income in fiscal year 2024. This represents an increase of 37.8% from the prior year.
Adaptimmune Therapeutics Plc earned -$0.05 per diluted share (EPS) in fiscal year 2024. This represents an increase of 44.4% from the prior year.
Cash & Balance Sheet
Adaptimmune Therapeutics Plc recorded an outflow of $74.1M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents an increase of 49.1% from the prior year.
Adaptimmune Therapeutics Plc held $91.1M in cash against $50.2M in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Adaptimmune Therapeutics Plc's gross margin was 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Adaptimmune Therapeutics Plc's operating margin was -38.6% in fiscal year 2024, reflecting core business profitability. No change is given against fiscal year 2023: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Adaptimmune Therapeutics Plc's net profit margin was -39.8% in fiscal year 2024, showing the share of revenue converted to profit. No change is given against fiscal year 2023: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Adaptimmune Therapeutics Plc's ROE was -597.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 309.4 percentage points from the prior year.
Capital Allocation
Adaptimmune Therapeutics Plc invested $149.1M in research and development in fiscal year 2024. This represents an increase of 17.8% from the prior year.
Adaptimmune Therapeutics Plc invested $886K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 81.1% from the prior year.
Not reported for fiscal year 2024.
ADAPY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.1M | $178.0M+195.3% | $60.3M+122.0% | $27.1M+341.5% | $6.1M+55.4% | $4.0M+252.8% | $1.1M-98.1% | $59.5M+57.3% | $37.8M+166.5% | $14.2M+43.8% | $9.9M+1096.5% | $825K | N/A |
| Cost of Revenue | N/A | $70K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $178.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $125.2M | $149.1M+17.8% | $126.5M-1.0% | $127.7M+15.0% | $111.1M+21.3% | $91.6M-6.1% | $97.5M-0.8% | $98.3M+12.5% | $87.4M+37.0% | $63.8M+164.3% | $24.1M+152.1% | $9.6M+27.8% | $7.5M |
| SG&A Expenses | $90.2M | $87.3M+18.7% | $73.5M+16.0% | $63.4M+10.6% | $57.3M+25.1% | $45.8M+5.5% | $43.4M-0.5% | $43.6M+40.2% | $31.1M+34.0% | $23.2M+123.7% | $10.4M+274.4% | $2.8M+121.0% | $1.3M |
| Operating Income | -$164.2M | -$68.8M+50.8% | -$139.7M+14.8% | -$164.0M-1.1% | -$162.2M-21.6% | -$133.4M+4.6% | -$139.8M-69.7% | -$82.4M-2.1% | -$80.7M-10.8% | -$72.8M-195.4% | -$24.6M-113.9% | -$11.5M-31.7% | -$8.7M |
| Interest Expense | N/A | $3.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $3.7M | $3.6M+167.7% | $1.3M-46.5% | $2.5M+215.7% | $791K+388.3% | $162K-33.1% | $242K-51.3% | $497K+10.2% | $451K-49.4% | $892K+265.6% | $244K+225.3% | $75K | N/A |
| Net Income | -$169.8M | -$70.8M+37.8% | -$113.9M+31.2% | -$165.5M-4.7% | -$158.1M-21.5% | -$130.1M+5.2% | -$137.2M-43.6% | -$95.5M-36.2% | -$70.1M+2.0% | -$71.6M-224.5% | -$22.1M-90.1% | -$11.6M-32.7% | -$8.7M |
| EPS (Diluted) | — | -$0.05+44.4% | -$0.09+47.1% | -$0.170.0% | -$0.17-13.3% | -$0.15+31.8% | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ADAPY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $246.0M-13.0% | $282.6M-14.1% | $328.9M-30.0% | $469.5M+4.1% | $451.1M+148.5% | $181.5M-34.4% | $276.7M-1.6% | $281.1M+19.9% | $234.5M-22.0% | $300.7M+439.4% | $55.7M | N/A |
| Current Assets | $188.2M-9.3% | $207.6M-18.7% | $255.4M-38.5% | $415.5M+4.3% | $398.2M+230.4% | $120.5M-47.9% | $231.1M+0.4% | $230.2M+15.8% | $198.8M-32.6% | $295.1M+443.4% | $54.3M | N/A |
| Cash & Equivalents | $91.1M-36.7% | $144.0M+33.3% | $108.0M-28.0% | $149.9M+163.6% | $56.9M+12.8% | $50.4M-26.3% | $68.4M-18.6% | $84.0M-47.1% | $158.8M-30.7% | $229.0M+347.5% | $51.2M | N/A |
| Inventory | $7.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.5M+77.1% | $821K-89.0% | $7.4M+888.7% | $752K+441.0% | $139K | N/A | $192K-6.8% | $206K-86.1% | $1.5M+36900.0% | $4K-97.1% | $138K | N/A |
| Total Liabilities | $234.1M-3.7% | $243.1M-1.6% | $247.0M-6.3% | $263.6M+139.8% | $109.9M+89.8% | $57.9M+94.0% | $29.9M-61.8% | $78.2M+14.3% | $68.4M+64.2% | $41.6M-21.1% | $52.8M | N/A |
| Current Liabilities | $64.5M-11.3% | $72.8M+12.8% | $64.5M+3.1% | $62.5M+60.1% | $39.1M+13.8% | $34.3M+40.5% | $24.4M-67.1% | $74.3M+84.5% | $40.3M+50.5% | $26.8M-49.3% | $52.8M | N/A |
| Long-Term Debt | $50.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $11.8M-70.0% | $39.5M-51.7% | $81.9M-60.2% | $206.0M-39.6% | $341.2M+176.0% | $123.6M-49.9% | $246.9M+21.6% | $203.0M+22.2% | $166.1M-35.9% | $259.0M+8659.0% | $3.0M+237.2% | -$2.2M |
| Retained Earnings | -$1.1B-6.9% | -$1.0B-12.5% | -$909.3M-22.2% | -$743.8M-27.0% | -$585.8M-28.5% | -$455.7M-43.1% | -$318.5M-37.5% | -$231.6M-43.4% | -$161.5M-141.3% | -$66.9M-122.2% | -$30.1M | N/A |
Not reported in any period shown, so not listed: Goodwill.
ADAPY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$190.0M | -$73.2M+48.0% | -$140.9M+0.6% | -$141.8M-1421.4% | $10.7M+120.0% | -$53.6M+52.4% | -$112.5M-7.8% | -$104.4M-92.2% | -$54.3M-12.8% | -$48.2M-62.4% | -$29.7M-180.5% | $36.8M+445.1% | -$10.7M |
| Capital Expenditures | $1.6M | $886K-81.1% | $4.7M-84.1% | $29.5M+244.0% | $8.6M+266.3% | $2.3M+47.0% | $1.6M-59.3% | $3.9M-84.1% | $24.6M+114.2% | $11.5M+126.5% | $5.1M+271.9% | $1.4M+718.0% | $167K |
| Free Cash Flow | -$191.7M | -$74.1M+49.1% | -$145.6M+15.0% | -$171.3M-8047.3% | $2.2M+103.9% | -$55.9M+51.0% | -$114.1M-5.4% | -$108.3M-37.2% | -$79.0M-32.3% | -$59.7M-71.7% | -$34.7M-198.0% | $35.5M+427.2% | -$10.8M |
| Investing Cash Flow | $1.8M | -$59.0M-133.4% | $176.5M+98.1% | $89.1M+17.6% | $75.8M+127.2% | -$278.9M-393.8% | $94.9M+643.9% | -$17.5M+86.2% | -$126.1M-810.1% | $17.8M+130.2% | -$58.8M | N/A | N/A |
| Financing Cash Flow | $1.3M | $78.7M+8848.8% | $880K-93.2% | $12.9M+291.3% | $3.3M-99.0% | $340.1M+92810.1% | $366K-99.6% | $102.7M-0.8% | $103.6M+609123.5% | $17K-100.0% | $274.9M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ADAPY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -38.6% | -231.8% | -604.0% | -2638.6% | -3370.5% | -12457.2% | -138.4% | -213.2% | -512.7% | -249.6% | -1396.5% | N/A |
| Net Margin | -39.8% | -188.9% | -609.5% | -2571.0% | -3286.8% | -12225.0% | -160.5% | -185.4% | -504.2% | -223.5% | -1406.2% | N/A |
| Return on Equity | -597.6%-309.4pp | -288.2%-86.1pp | -202.1%-125.3pp | -76.8%-38.6pp | -38.1%+72.8pp | -110.9%-72.2pp | -38.7%-4.1pp | -34.5%+8.5pp | -43.1%-34.6pp | -8.5%+383.8pp | -392.3% | N/A |
| Return on Assets | -28.8%+11.5pp | -40.3%+10.0pp | -50.3%-16.6pp | -33.7%-4.8pp | -28.8%+46.7pp | -75.6%-41.1pp | -34.5%-9.6pp | -24.9%+5.6pp | -30.5%-23.2pp | -7.3%+13.5pp | -20.8% | N/A |
| Current Ratio | 2.92+0.1x | 2.85-1.1x | 3.96-2.7x | 6.64-3.5x | 10.19+6.7x | 3.51-5.9x | 9.46+6.4x | 3.10-1.8x | 4.94-6.1x | 11.02+10.0x | 1.03 | N/A |
| Debt-to-Equity | 4.24-1.9x | 6.15+3.1x | 3.02+1.7x | 1.28+1.0x | 0.32-0.1x | 0.47+0.3x | 0.12-0.3x | 0.390.0x | 0.41+0.3x | 0.16-17.7x | 17.85 | N/A |
| FCF Margin | -41.6% | -241.5% | -630.9% | 35.0% | -1413.1% | -10169.3% | -182.0% | -208.7% | -420.3% | -352.0% | 4299.3% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where Adaptimmune Therapeutics Plc Ranks
Frequently Asked Questions
What is Adaptimmune Therapeutics Plc's annual revenue?
Adaptimmune Therapeutics Plc (ADAPY) reported $178.0M in total revenue for fiscal year 2024. This represents a 195.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Adaptimmune Therapeutics Plc's revenue growing?
Adaptimmune Therapeutics Plc (ADAPY) revenue grew by 195.3% year-over-year, from $60.3M to $178.0M in fiscal year 2024.
Is Adaptimmune Therapeutics Plc profitable?
No, Adaptimmune Therapeutics Plc (ADAPY) reported a net income of -$70.8M in fiscal year 2024, with a net profit margin of -39.8%.
What is Adaptimmune Therapeutics Plc's EBITDA?
Adaptimmune Therapeutics Plc (ADAPY) had EBITDA of -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Adaptimmune Therapeutics Plc have?
As of fiscal year 2024, Adaptimmune Therapeutics Plc (ADAPY) had $91.1M in cash and equivalents against $50.2M in long-term debt.
What is Adaptimmune Therapeutics Plc's gross margin?
Adaptimmune Therapeutics Plc (ADAPY) had a gross margin of 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Adaptimmune Therapeutics Plc's operating margin?
Adaptimmune Therapeutics Plc (ADAPY) had an operating margin of -38.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Adaptimmune Therapeutics Plc's net profit margin?
Adaptimmune Therapeutics Plc (ADAPY) had a net profit margin of -39.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Adaptimmune Therapeutics Plc's return on equity (ROE)?
Adaptimmune Therapeutics Plc (ADAPY) has a return on equity of -597.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Adaptimmune Therapeutics Plc's free cash flow?
Adaptimmune Therapeutics Plc (ADAPY) recorded an outflow of $74.1M in free cash flow during fiscal year 2024. This represents a 49.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Adaptimmune Therapeutics Plc's operating cash flow?
Adaptimmune Therapeutics Plc (ADAPY) recorded an outflow of $73.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Adaptimmune Therapeutics Plc's total assets?
Adaptimmune Therapeutics Plc (ADAPY) had $246.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Adaptimmune Therapeutics Plc's capital expenditures?
Adaptimmune Therapeutics Plc (ADAPY) invested $886K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Adaptimmune Therapeutics Plc spend on research and development?
Adaptimmune Therapeutics Plc (ADAPY) invested $149.1M in research and development during fiscal year 2024.
What is Adaptimmune Therapeutics Plc's current ratio?
Adaptimmune Therapeutics Plc (ADAPY) had a current ratio of 2.92 as of fiscal year 2024, which is generally considered healthy.
What is Adaptimmune Therapeutics Plc's debt-to-equity ratio?
Adaptimmune Therapeutics Plc (ADAPY) had a debt-to-equity ratio of 4.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adaptimmune Therapeutics Plc's return on assets (ROA)?
Adaptimmune Therapeutics Plc (ADAPY) had a return on assets of -28.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Adaptimmune Therapeutics Plc's cash runway?
Based on fiscal year 2024 data, Adaptimmune Therapeutics Plc (ADAPY) had $91.1M in cash against an annual operating cash burn of $73.2M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Adaptimmune Therapeutics Plc's Altman Z-Score?
Adaptimmune Therapeutics Plc (ADAPY) has an Altman Z-Score of -5.80, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Adaptimmune Therapeutics Plc's Piotroski F-Score?
Adaptimmune Therapeutics Plc (ADAPY) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adaptimmune Therapeutics Plc's earnings high quality?
Adaptimmune Therapeutics Plc (ADAPY) reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Adaptimmune Therapeutics Plc cover its interest payments?
Adaptimmune Therapeutics Plc (ADAPY) reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.